Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the period ending October 2014. The document serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is limited to a specific transaction notification and does not contain financial performance data.
Material Changes
The filing reports a specific increase in the notional allocation of GSK American Depositary Shares (ADSs) for a connected person:
- Connected Person: Dr K Slaoui (Connected person of Dr M Slaoui).
- Transaction Date: October 10, 2014.
- Notification Date: October 11, 2014.
- Number of ADSs: 6.
- Price per ADS: $44.12.
- Cause: Revaluation of the cash element of the notional investment held within the GSK 401K plan.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items beyond the specific transaction noted above.
Investor Verification Points
- Verify the identity of Dr K Slaoui and their relationship to Dr M Slaoui to confirm connected person status.
- Confirm the impact of the GSK 401K plan revaluation on the notional investment allocation.
- Note that this filing does not reflect broader company financial performance or strategic changes.